Ryvu Therapeutics reported safety and efficacy data from the Phase Ib dose-escalation study of RVU120 in patients with acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (HR-MDS).

The data will be presented at the Annual European Haematology Association (EHA) 2023 Hybrid Congress, on June 9 in Frankfurt, Germany.

The open label, dose-escalation Phase Ib study (NCT04021368) of RVU120, small molecule CDK8/19 inhibitor, in patients with AML or HR-MDS, evaluates safety, tolerability, preliminary anti-leukemic activity, as well as pharmacokinetic and pharmacodynamic profiles.

Of the total 24 patients evaluated, 11 reported a favourable safety profile and clinical benefit.

One patient with NMP1-mutated AML treated at 75 mg achieved complete remission. Another patient with AML refractory to prior lines of therapy became eligible for allogeneic stem cell transplantation after treatment at the 110 mg dose.

In addition, enhanced efficacy was reported in the preclinical data of RVU120 in combination with the JAK1/2 inhibitor ruxolitinib (RUX) in myeloproliferative neoplasms from a separate trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Treatment with RVU120 monotherapy and in combination with RUX reported significant reductions of disease manifestation, specifically reductions in WBCs, disease reporter percentages, splenomegaly, and bone marrow/spleen fibrosis, as well as stimulated normal haematopoiesis.

 “These findings reinforce the potential of co-targeting CDK8/19 and JAK1/2 as a promising approach in the treatment of myeloproliferative neoplasms,” said Hendrik Nogai, Chief Medical Officer of the Polish company.

According to GlobalData, AbbVie’s Venclexta/Venclyxto is the market leader in AML with forecasted global sales of $5 billion by 2028.

GlobalData is the parent company of Clinical Trials Arena.